Traveler Care Launches Global Medical Dispatch Platform to Help Travel Insurance Companies Cut ER Claims by 80%
A Concierge Alternative to the Emergency Room
Traveler Care connects travel insurers and their policyholders to a network of licensed, on-call providers who visit travelers in their accommodations - typically within 60-90 minutes. Conditions such as flu, food poisoning, dehydration, allergic reactions, UTIs, sprains, and wound care are treated on-site, eliminating the need for an ER visit.
"In most cases, travelers just need a doctor - not a hospital admission," said Eli Ofel, founder of Traveler Care. "We've built a scalable, insurer-ready solution that saves money and delivers a far better traveler experience."
Reduce Claims by $10,000+ Per Visit
On average, a non-emergency ER visit costs travel insurers $13,000 to $17,000. Traveler Care treats the same conditions in-room for $1,700 to $3,000 - including diagnostics like mobile X-ray, ultrasound, IV therapy, and wound treatment.
Pilot results have shown:- 83% reduction in ER claim volume- $10,000+ savings per case avoided- Higher satisfaction scores among travelers
Built for Travel Insurance Partners
Traveler Care is fully designed for insurance integration - with white-label and API options available for TPAs, underwriters, and global assistance networks.
Platform features:- Nationwide U.S. coverage (with international expansion underway)- A robust dispatch network, for example companies like Leaa Health, Sickday, Heal, DocGo and more, any location that the travel insurance is experiencing high volume travel care will create a solution for that particular location within 60 days.- HIPAA-compliant documentation + one-click claims integration- Supports care delivery to hotels, Airbnbs, resorts, and serviced apartments
Now Onboarding Insurance Companies Worldwide
"We believe travel insurance companies shouldn't just pay for care - they should deliver it smarter," said Ofel. "With Traveler Care, you lower claims without compromising care."
Insurance providers, TPAs, and global assistance companies are invited to partner and deploy in-room urgent care as part of their medical benefit stack.
Contact
To schedule a private demo or receive our ROI case study:Visit www.traveler.careEmail: partners@traveler.carePhone: +1 (347) 733-0563
About Eli Ofel
Eli Ofel is a serial entrepreneur and visionary behind multiple AI- and tech-powered platforms in healthcare, finance, and transportation. He is the founder and CEO of Traveler Care, Run.Vet, Leaa Health, 02.Market, and Lender.Market. With over 20 years of experience in healthcare operations, insurance workflows, and mobile logistics, Ofel brings a proven ability to bridge patient needs with scalable platform solutions - saving time, money, and lives.
SOURCE: Traveler care
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
13 minutes ago
- Indianapolis Star
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
SHELTON, CT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union. NV-387 is possibly the only drug candidate that has been shown to be effective and safe in animal model studies of Measles virus in humanized h-CD150+ knock-in mice, as reported previously by NanoViricides. NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. The development of NV-387 as a treatment for Measles can be accelerated under the US FDA programs. Measles is considered a rare orphan disease in the USA. As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval [1]. The Company also plans to explore a 'Fast Track' designation for the NV-387 Measles indication. If granted, a drug approval can occur on the basis of a successful Phase II clinical trial without requiring a Phase III clinical trial, which significantly reduces the timeline to approval. Measles has become an important disease of concern globally in the recent years for several reasons. Most importantly, Measles disease can wipe out the previously learned immunity of the patient against many infections, including from prior infections, and non-live virus vaccines, making the population vulnerable to viruses that were encountered previously. This is because Measles virus attacks the CD150-bearing immune cells that are responsible for memorizing the prior infections and mounting defenses against them later. Measles is possibly the most communicable diseases, spreading through aerosol, that is known to humans. In patients, it produces severe morbidity with skin rash, pain, fatigue, and other syndromes. Rarely it can cause a brain disease. Measles mostly affects children. There were a total of 1,319 confirmed measles cases reported in the USA as of July 22, breaking the most recent record of 1,274 cases in 2019. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although in 2025 there were three deaths to date. Canada is having a much worse Measles season than the USA, with more than 3,800 cases [2] to date in 2025. A Measles holiday warning has been issued in the UK this year [3]. England itself had more than 3,000 cases of Measles in 2024. In the European Region, 127,350 measles cases were reported for 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and the United Nations Children's Fund (UNICEF) [4]. Worldwide, Measles cases continue to occur every year. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, while in 2024 there were about 360,000 confirmed cases, according to the WHO [5]. A sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity ('herd immunity'). Such a high rate is becoming increasingly difficult to achieve even in developed countries where access to vaccination is not an issue. While growing vaccine hesitancy is considered an important reason for the fall in Measles vaccination rates, two other factors are of importance as well: (i) The overall population in the industrialized world, as well as in developing world, has increased frequency of immune dysfunction, obesity, and diabetes. The people with immune dysfunction or immune compromise are less likely to benefit from almost any standard vaccination as compared to healthy people and are likely to result in breakthrough infections. (ii) Additionally, the current vaccine for Measles is a live attenuated vaccine of the 1968 era, and the virus has evolved well past that, although so far the Measles virus strains continue to be susceptible to antibodies produced from the standard vaccine; this can change with continuing circulation of the virus in vaccinated persons and can result in a virus that can substantially defeat the vaccine [6]. Further, vaccine hesitancy itself is not irrational because the standard Measles vaccine is a live attenuated vaccine to be given to infants at early age; it is a virus infection that continues to remain in the subject, which is why it provides lifelong immunity. Measles infection itself also provides lifelong immunity that includes the current strains of the virus. Thus, the Company projects continuing Measles cases worldwide, that require a drug to control the disease in the patient and its spread to others. We believe NV-387 fills this important medical need. There is no approved drug for treatment of Measles at present. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ View the original press release on ACCESS Newswire The post Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides appeared first on DA80 Hub.
Time Business News
8 hours ago
- Time Business News
Finding a Reputable Rehab for Sale Near You
In the behavioral health industry, purchasing a rehab facility can be one of the most lucrative and impactful investments you can make—if you choose wisely. A reputable rehab center not only comes with a proven operational structure and licensure but also provides a platform for sustainable growth and community impact. Whether you're an experienced operator looking to expand or a first-time buyer entering the market, understanding how to evaluate and secure the right rehab for sale near you is crucial to long-term success. For entrepreneurs seeking to enter the behavioral health space, purchasing an existing treatment center can offer a streamlined path to ownership. When evaluating a drug rehab for sale, it's critical to assess not just the physical infrastructure, but also the program's reputation, licensure status, payer contracts, and staff qualifications. Financial due diligence, including revenue sources and profitability trends, ensures a sound investment. Acquiring a rehab with a proven track record reduces startup risk and allows new owners to build upon an established foundation. With the right vision, such a purchase can be both a business opportunity and a social impact mission. Before searching for a rehab center for sale, it's important to study the behavioral health market in your region. What are the prevailing trends in addiction treatment and mental health care? Is there growing demand for specific levels of care such as detox, residential treatment, or intensive outpatient programs? Areas with underserved populations or limited access to treatment are often prime markets for investment. A local market assessment can help you identify regions where a rehab center is not only needed but also likely to thrive. When exploring how to make the right investment in behavioral health, the quality and reputation of the facility are paramount. A reputable rehab for sale should include existing licenses with state health departments or accrediting bodies such as CARF or The Joint Commission (JCAHO). It should have a track record of compliance with local and federal regulations, including HIPAA. Operationally, the business should have an experienced clinical team, documented policies and procedures, and steady client flow. Don't just look at the property—evaluate the entire system behind the service delivery. Financial transparency is one of the most critical indicators of a worthwhile investment. Analyze at least 3 years of financial statements to verify income sources, insurance reimbursements, and operating expenses. Ask for census data, payer mix breakdowns, and EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) figures. If you're wondering how to start an addiction treatment center through acquisition, you'll want to ensure the center is generating consistent cash flow or has the potential to do so with reasonable changes. The location of a rehab facility plays a significant role in its long-term success. Proximity to hospitals, transportation hubs, and referral partners can directly influence admissions. Just as important, ensure the property complies with local zoning laws for healthcare use. A rehab that's already operating in a compliant, licensed, and zoned building eliminates many of the hurdles that come with starting from scratch. Additionally, local community sentiment about addiction treatment centers can either support or hinder your operations—so consider reputational factors within the neighborhood. Rehab centers are highly regulated entities, and any reputable business for sale should have proper licensure. Whether you're buying a detox facility, residential center, or outpatient clinic, confirm that all state and federal licenses are active and transferrable. During your evaluation, it's wise to engage consultants who specialize in DHCS Licensing for Behavioral Health or equivalent state-level authorities. They can help you identify any red flags in the facility's history, including citations, fines, or unresolved compliance issues. People are at the heart of any rehab business. Beyond tangible assets, evaluate the strength and stability of the clinical and administrative staff. A well-trained team, with certified counselors, licensed therapists, and experienced management, adds immediate value to your investment. When considering how to start a rehab center through acquisition, retaining the existing team can ensure continuity of care and smoother transitions post-sale. Employee turnover, on the other hand, may signal deeper cultural or operational problems that could delay growth. Finding a rehab for sale near you offers several benefits. First, you're more likely to understand the nuances of your local regulatory climate and healthcare ecosystem. Second, due diligence is easier when you can physically visit the site, meet the staff, and speak with local stakeholders. Third, proximity allows for easier post-acquisition oversight if you're planning to manage operations yourself. Local investments also allow you to tap into regional networks of referral partners, insurance providers, and marketing opportunities. If you're unfamiliar with behavioral health transactions, working with a broker who specializes in rehab sales can streamline the process. These professionals often have access to off-market listings and understand how to value businesses based on client census, payer mix, and operational performance. Additionally, consultants with experience in licensing, accreditation, and due diligence can safeguard your investment and help you navigate the complexities of the behavioral healthcare industry. When you find a rehab for sale that meets your financial, operational, and clinical criteria, move forward with a clear transition plan. Outline how you will retain key staff, manage client care continuity, and address any operational gaps. Post-acquisition, your first few months will set the tone for long-term success. It's wise to invest in leadership training, quality improvement initiatives, and possibly rebranding to reflect your values and vision. Understanding the financial dynamics of the mental health sector is essential for any investor, operator, or stakeholder aiming to succeed. Accurate forecasting, payer mix analysis, and cost structure reviews are vital for long-term stability. In the middle of these evaluations lies the importance of behavioral health finance valuation, which helps determine the true worth of services based on revenue sources, regulatory risk, and clinical outcomes. As market demand for behavioral health continues to rise, knowing how to assess economic value is no longer optional—it's a critical skill for sustainable decision-making and organizational growth. Making the right investment in a rehab center isn't just about financial returns—it's about delivering high-quality care to people in need. By focusing on compliance, operational readiness, and community impact, you position yourself for both profitability and purpose. As more investors seek mission-aligned ventures in healthcare, acquiring a reputable rehab near you could be your next great move in a growing and meaningful industry. TIME BUSINESS NEWS
Time Business News
a day ago
- Time Business News
Launching a Rehab Center: Practical Business Steps
Starting a rehab center is both a business opportunity and a mission-driven venture. With the rising need for addiction recovery and behavioral health services, opening a facility that offers structured, effective treatment can make a profound impact on your community. But success doesn't happen overnight—it requires a practical approach grounded in compliance, operations, and long-term strategy. Here's how to turn your rehab center vision into a functioning, results-driven business. Launching a therapeutic center for recovery requires dedication, planning, and compliance. From selecting the right location to designing a service model tailored to community needs, each decision lays the foundation for impact. Regulatory steps like zoning permits, licensing, and accreditation are essential checkpoints. Financial forecasting and staffing with credentialed professionals ensure operational stability. Understanding how to start a rehab facility involves researching state-specific regulations, creating clinical protocols, and aligning with insurance providers for reimbursement. A well-structured facility isn't just a business—it's a commitment to transforming lives, providing support systems, and restoring hope for individuals battling addiction. Before anything else, you must clearly define the types of services your facility will offer. Will you operate as a residential inpatient center, a partial hospitalization program (PHP), or an intensive outpatient program (IOP)? Each option involves different licensing requirements, staffing structures, and cost models. Align your treatment model with local demand and your clinical vision to ensure sustainability and effectiveness. Every state has its own regulatory environment, but the process generally starts with facility licensing through your state's Department of Health or behavioral health authority. If you're in California, you'll need DHCS Licensing for Behavioral Health. Compliance with HIPAA and state-specific documentation rules is mandatory. Start gathering application materials early and consider hiring a consultant who specializes in behavioral health regulations to avoid common pitfalls. A rehab center needs a structured business plan to attract investors, obtain financing, and provide internal direction. Your plan should include a mission statement, target population, competitive analysis, marketing strategy, and detailed financial projections. Include both startup costs (real estate, licensing, staff onboarding) and operational costs (payroll, insurance billing systems, supplies). A clear business model will guide your initial decisions and future expansion. Your location must balance convenience, privacy, and zoning compliance. Look for properties zoned for healthcare or residential treatment and verify that they meet all safety and accessibility codes. If you plan to buy an existing facility, conduct a thorough due diligence process. A rehab facility for sale may already have a license, which can significantly accelerate your launch timeline. Staffing is one of the most important components of a successful rehab center. Hire experienced medical directors, clinicians, case managers, and support staff who understand treatment protocols and legal obligations. Strong leadership and a compassionate, well-trained team create a therapeutic environment that attracts clients and fosters recovery. To increase your center's credibility and access to insurance clients, pursue accreditation through CARF or JCAHO. These organizations evaluate your policies, staff credentials, and quality assurance practices. Begin the process of contracting with insurance providers early—credentialing can take months. Insurance-based revenue is essential for long-term financial health, especially in outpatient settings. From client intake to treatment tracking, every part of your operation must follow a clear process. Invest in a reliable electronic health record (EHR) system and develop procedures for documentation, medication management, and emergency response. Systems that support consistency and compliance reduce liability and increase staff efficiency. Marketing your rehab center means building trust and visibility. Launch a professional website, optimize for local SEO, and use Google Business tools to appear in treatment searches. Build referral networks with hospitals, therapists, court systems, and community partners. Focus on messaging that emphasizes your unique approach, staff expertise, and client success. Once your rehab center is operational, ongoing performance evaluation is essential. Track KPIs like admissions, average length of stay, client satisfaction, and insurance collections. Collect feedback regularly and adapt your services based on outcomes and regulatory changes. Continuous improvement ensures your center remains effective, compliant, and competitive in the behavioral health space. Establishing a behavioral health center demands more than clinical expertise—it requires a deep understanding of compliance. One of the most critical components for operating legally in California is securing DHCS Licensing for behavioral health programs. This process involves meeting rigorous standards in facility safety, staff qualifications, program structure, and patient care protocols. Providers must submit detailed applications, undergo inspections, and maintain ongoing compliance with Department of Health Care Services regulations. While the licensing journey may seem complex, it ensures quality and accountability across services. Successfully navigating it builds a foundation of trust with both clients and regulatory bodies. Launching a rehab center successfully requires more than a good idea—it takes practical steps rooted in regulation, planning, staffing, and strategic growth. By defining your services, securing licenses, building a skilled team, and implementing efficient operations, you position your facility for both clinical excellence and business sustainability. With careful execution, your rehab center can become a powerful force for recovery and change in your community. TIME BUSINESS NEWS
